Publications

Publication Search

Search for publications by

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4.

Abstract

Endocrine resistance is a major limitation to the successful treatment of estrogen receptor-positive (ER+) breast cancer and the EGFR and ErbB2 receptor tyrosine kinases are involved in this process. A recent study now implicates the other 2 ErbB family members, ErbB-3 and -4. Exposure of ER+ breast cancer cells to the pure antiestrogen, fulvestrant, increased levels of ErbB-3 or ErbB-4 and sensitivity to the growth stimulatory effects of heregulin ?1, a potent ligand for these receptors. Thus, the initial growth inhibitory effects of fulvestrant appear compromised by cellular plasticity that allows rapid compensatory growth stimulation via ErbB3/4. Further evaluation of pan-erbB receptor inhibitors in endocrine resistant disease appears warranted.

ISBN 1465-5411 (Linking)
Authors Sutherland, R.L.
Publisher Name BREAST CANCER RES
Published Date 2011-07-01 00:00:00
Published Volume 13
Published Issue 3
Published Pages 106
URL http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21639949
Status Published In-print
OpenAccess Link https://publications.gimr.garvan.org.au/download.php?11010_11444/11_Sutherland_BCR.pdf